Isatuximab plus pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: Subgroup analysis by prior anti-CD38 exposure from the phase 3 IRAKLIA trial.
Albert Oriol Rocafiguera, Marek Hus, Raimundo Gazitúa, Aijun Liao et autres
0 citationsJournal of Clinical Oncology